Atypical chronic myeloid leukaemia (aCML) is a rare chronic myeloproliferative disorder with a poor prognosis.
Case report
This case report presents two cases of male geriatric patients, both referred from primary care in rural areas and received at an urban clinic in a tertiary care hospital on separate instances. The first patient complained of low-grade fever (on/off), generalized body aches, rapid weight loss and shortness of breath for the last 2 months. The second patient arrived pale looking with symptoms of generalized body aches, dizziness and anorexia. Both patients were diagnosed to have aCML according to the World Health organization criteria.
Management & outcome
Both the patients were from a low economic bracket and were treated with Hydroxyurea a relatively economic medicine successfully. The follow-up lasted for 12 months in both cases. No progression to acute myeloid leukaemia (AML) or relapse was observed.
Discussion
This case report shows the promising results of Hydroxyurea in treating aCML and can be a cost effective alternate to other expensive treatments (allogeneic hematopoietic stem cell transplantation) and expensive medicines in lower and middle-income countries especially for resource-limited patients. These two cases show promising evidence for further studies to evaluate and conduct pharmaco-economic evaluations as well as clinical trials to compare hydroxyurea with other available alternative treatments for an affordable therapeutic option towards prevention of relapse and disease free survival after aCML.
BennettJCatovskyDDanielM, et al.The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: proposals by the French-American-British cooperative leukaemia group. Br J Haematol1994; 87: 746–754.
2.
Drozd-SokołowskaJEWaszczuk-GajdaAMądryK,et al.Atypical chronic myeloid leukaemia - a rare subtype of myelodysplastic/myeloproliferative neoplasm. Contemp Oncol (Pozn)2018; 22: 14–19.
3.
GotlibJ. How I treat atypical chronic myeloid leukaemia. Blood2017; 129: 838–845.
4.
BrecciaMBiondoFLatagliataR,et al.Identification of risk factors in atypical chronic myeloid leukaemia. Haematologica2006; 91: 1566–1568.
5.
ShuvaevVKrutikovaKMenshakovaS, et al. Atypical chronic myeloid leukaemia challenge in Russian hematology practice. Blood. 2018;132(Supplement 1):5483.
6.
GiriSPathakRMartinMG,et al.Characteristics and survival of BCR/ABL negative chronic myeloid leukaemia: a retrospective analysis of the surveillance, epidemiology and End results database. Ther Adv Hematol2015; 6: 308–312.
SaqlainNAhmedN. Atypical chronic myeloid leukaemia, BCR-ABL1 negative, in a 5-month baby-ARare presentation. J Coll Physicians Surg Pak2016; 26: 103–105.
10.
FreedmanJLDesaiAVBaileyLC, et al.Atypical chronic myeloid leukaemia in two pediatric patients. Pediatr Blood Cancer2016; 63: 156–159.
11.
WangSAHasserjianRPFoxPS, et al.Atypical chronic myeloid leukaemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood, The Journal of the American Society of Hematology2014; 123: 2645–2651.
12.
HernandezJDel CañizoMCuneoA, et al.Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukaemia. Ann Oncol2000; 11: 441–444.
13.
KongJHNamHGoT-H,et al.Characteristics and survival of patients with atypical chronic myeloid leukaemia. Blood Res2019; 54: 233–236.
14.
SabaRBhamidipatiPKCashenA. Not So typical: development of atypical chronic myeloid leukaemia in a patient With chronic myeloid leukaemia. JCO Precision Oncology2017; 1: 1–15.
15.
GaltonD. Haematological differences between chronic granulocytic leukaemia, atypical chronic myeloid leukaemia, and chronic myelomonocytic leukaemia. Leukaemia & Lymphoma1992; 7: 343–350.
16.
CannellaLBrecciaMLatagliataR,et al.Clinical and prognostic features of patients with myelodysplastic/myeloproliferative syndrome categorized as unclassified (MDS/MPD-U) by WHO classification. Leukaemia Res2008; 32: 514–516.
17.
PatnaikMMBarracoDLashoTL, et al.Targeted next generation sequencing and identification of risk factors in W orld H ealth O rganization defined atypical chronic myeloid leukaemia. Am J Hematol2017; 92: 542–548.
18.
OnidaFBallGKantarjianHM, et al.Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukaemia. Cancer2002; 95: 1673–1684.
19.
HausmannHBhattVRYuanJ,et al.Activity of single-agent decitabine in atypical chronic myeloid leukaemia. J Oncol Pharm Pract2016; 22: 790–794.
AsifNAnwarTChaudaryH, et al.Treatment response to hydroxyurea in beta thalassemia. J Islamabad Med Dent Col2014; 3: 48–52.
22.
AnsongDAkotoAOOclooD,et al.Sickle cell disease: management options and challenges in developing countries. Mediterr J Hematol Infect Dis2013; 5: 2013062–2013068.
23.
MulakuMOpiyoNKarumbiJ,et al.Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. Arch Dis Child2013; 98: 908–914.
24.
ObaroSK. Hydroxyurea for sickle-cell anaemia in Africa: mind the gap. Lancet Glob Health2015; 3: 124–125.
25.
ShamsiT. Medical management of b-thalassaemia without blood transfusion: a myth or a reality?2013; 63: 304–305.
ItonagaHOtaSIkedaT, et al.Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukaemia and chronic neutrophil leukaemia: a retrospective nationwide study in Japan. Leuk Res2018; 75: 50–57.
28.
HashmiSKSrivastavaARasheedW, et al.Cost and quality issues in establishing hematopoietic cell transplant program in developing countries. Hematol Oncol Stem Cell Ther2017; 10: 167–172.
29.
OnidaFde WreedeLCvan BiezenA, et al.Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the chronic malignancies working party of the european society for blood and marrow transplantation. Br J Haematol2017; 177: 759–765.
30.
ShamsiTSHashmiKAdilS, et al. The stem cell transplant program in Pakistan—the first decade. Bone Marrow Transplantation 2008; 42(1): S114-1S7. https://doi.org/10.1038/bmt.2008.137.
MarumoAMizukiTTanosakiS. Atypical chronic myeloid leukaemia achieving good response with azacitidine. Indian J Cancer2019; 56: 354–355.
33.
SaqlainNAhmedN. Atypical chronic myeloid leukaemia, BCR-ABL1 negative, in a 5-month baby - ARare presentation. J Col Phys Sur Pak2016; 26: 103–105.
34.
AliMKuroiwaC. Accurate record keeping in referral hospitals in Pakistan's North west frontier province and punjab: a crucial step needed to improve maternal health. JPMA2007; 57: 445.
35.
BelkhairJRaissiAElyahyaouiH,et al.Atypical chronic myeloid leukaemia BCR-ABL 1 negative: a case report and literature review. Leukaemia Res Rep2019; 12: 100172.
